糖尿病与肥胖/脂代谢异常　　

      [摘要] 目的 采用18F脱氧葡萄糖(FDG)正电子发射断层扫描(PET)和计算机断层扫描(CT)成像评估吡格列酮对内脏脂肪组织代谢活性的影响。 方法 62例研究对象被随机分为吡格列酮组和格列美脲组，共治疗16周。治疗前后利用FDG-PET和CT对T2DM或IGT患者脂肪组织行成像分析，同时，检测血脂及血糖相关炎症标志物。 结果 吡格列酮组在治疗后内脏脂肪面积[(131.5±51.0) vs (109.1±45.0) cm2]及内脏脂肪活性[(0.58±0.15) vs (0.47±0.11)]较治疗前减少(P<0.05);格列美脲组治疗后内脏脂肪面积及内脏脂肪活性较治疗前变化差异无统计学意义(P>0.05)。 结论 吡格列酮能减少T2DM或IGT患者内脏脂肪量及其代谢活性。

　　[关键词] 吡格列酮;格列美脲;糖尿病，2型;糖耐量受损; 内脏脂肪

　　[Abstract] Objective To study the effects of pioglitazone on visceral fat tissue metabolic activity in patients with type 2 diabetes mellitus or impaired glucose tolerance by using 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) and computed tomography (CT) imaging. Methods FDG-PET and CT imaging were performed in 62 patients with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT).Lipid and glycemic profiles and inflammatory markers were detected in all patients. These patients randomly received treatments with either pioglitazone or glimepiride for 16 weeks. Results After 16 weeks, pioglitazone-treated groupversus glimepiride-treated groupshowed a significantly decreased visceral fat area[(109.1±45.0) vs(122.5±52.0 )cm2] and a significantly decreased visceral fat metabolic activity(0.47±0.11)vs(0.55±0.11)(P<0.05). Conclusion Our study indicates that pioglitazone decreases the visceral fat volume and its metabolic activity in patients with T2DM or IGT.

　　[Key word] Pioglitazone ;Glimepiride ;Diabetes mellitus, type 2;Impaired glucose tolerance;Visceral fat